Drugs / Mycophenolate acid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT00941824 | Feb 2009 → Mar 2010 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT00658333 | Mar 2008 → Mar 2009 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03504241 Background | Jul 2018 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00267189 Background | Nov 2005 → Nov 2007 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 4 | NCT00170846 Background | Feb 2005 → Oct 2009 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| — | NCT01649609 Comparator | Mar 2012 → Dec 2016 | BK-virus nephropathy | Columbia University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycophenolate acid | “Mycophenolate acid (MPA) has been developed and approved in combination with cyclosporine and has been used in kidney transplantation for more than a decade.” NCT00941824 ↗ |
| Known as | MPA | “Mycophenolate acid (MPA) has been developed and approved in combination with cyclosporine and has been used in kidney transplantation for more than a decade.” NCT00941824 ↗2“Drug: Mycophenolate acid (MPA)/Azathioprine (AZA)” NCT00170846 ↗ “Mycophenolate acid (MPA)/ Azathioprine (AZA)” NCT00267189 ↗ |